An experimental study to identify the potential role of pharmacogenomics in determining the occurrence of oxaliplatin-induced liver injury

HPB

Volumn 15, Issue 8, 2013, Pages 581-587

  Robinson, Stuart M ^a,b   Mann, Jelena ^a   Manas, Derek M ^b   Mann, Derek A ^a   White, Steven A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; HISTONE H2AX; OXALIPLATIN; WILSON DISEASE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; DNA DAMAGE; DNA REPAIR; DRUG METABOLISM; DRUG TRANSPORT; EXPERIMENTAL STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PHARMACOGENOMICS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TOXIC HEPATITIS;

EID: 84880154512     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/hpb.12010     Document Type: Conference Paper

References (31)

1. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24: 2065-2072.
2. Tamandl D, Klinger M, Eipeldauer S, Herberger B, Kaczirek K, Gruenberger B, et al. (2011) Sinusoidal obstruction syndrome impairs longterm outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol 18: 421-430.
3. Aloysius MM, Zaitoun AM, Beckingham IJ, Neal KR, Aithal GP, Bessell EM, et al. (2007) The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study. Virchows Arch 451: 943-948.
4. Hubert C, Fervaille C, Sempoux C, Horsmans Y, Humblet Y, Machiels JP, et al. (2010) Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases. Surgery 147: 185-194.
5. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet 371: 1007-1016.
6. Keizman D, Maimon N, Ish-Shalom M, Buchbut D, Inbar M, Klein B, et al. (2010) An animal model for chemotherapy-associated steatohepatitis and its prevention by the oral administration of fatty acid bile acid conjugate. Cancer 116: 251-255.
7. Rickenbacher A, DeOliveira ML, Tian Y, Jang JH, Riener MO, Graf R, et al. (2011) Arguments against toxic effects of chemotherapy on liver injury and regeneration in an experimental model of partial hepatectomy. Liver Int 31: 313-321.
8. Boughattas NA, Levi F, Fournier C, Lemaigre G, Roulon A, Hecquet B, et al. (1989) Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice. Cancer Res 49: 3362-3368.
9. Kweekel DM, Gelderblom H, Guchelaar HJ,. (2005) Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 31: 90-105.
10. Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, et al. (2002) Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 62: 6559-6565.
11. Safaei R, Katano K, Samimi G, Naerdemann W, Stevenson JL, Rochdi M, et al. (2004) Cross-resistance to cisplatin in cells with acquired resistance to copper. Cancer Chemother Pharmacol 53: 239-246.
12. Holzer AK, Manorek GH, Howell SB,. (2006) Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol 70: 1390-1394.
13. Larson CA, Blair BG, Safaei R, Howell SB,. (2009) The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol 75: 324-330.
14. Liu JJ, Jamieson SM, Subramaniam J, Ip V, Jong NN, Mercer JF, et al. (2009) Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity. Cancer Chemother Pharmacol 64: 847-856.
15. Lee YY, Choi CH, Do IG, Song SY, Lee W, Park HS, et al. (2011) Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy. Gynecol Oncol 122: 361-365.
16. Blair BG, Larson CA, Adams PL, Abada PB, Safaei R, Howell SB,. (2010) Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells. Mol Pharmacol 77: 912-921.
17. Blair BG, Larson CA, Safaei R, Howell SB,. (2009) Copper transporter 2 regulates the cellular accumulation and cytotoxicity of cisplatin and carboplatin. Clin Cancer Res 15: 4312-4321.
18. Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, Tomioka M, et al. (2004) Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res 10: 4661-4669.
19. Komatsu M, Sumizawa T, Mutoh M, Chen ZS, Terada K, Furukawa T, et al. (2000) Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 60: 1312-1316.
20. Martinez-Balibrea E, Martinez-Cardus A, Musulen E, Gines A, Manzano JL, Aranda E, et al. (2009) Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy. Int J Cancer 124: 2905-2910.
21. Robinson S, Manas DM, Pedley I, Mann D, White SA,. (2011) Systemic chemotherapy and its implications for resection of colorectal liver metastasis. Surg Oncol 20: 57-72.
22. Longley DB, Harkin DP, Johnston PG,. (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338.
23. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31: 1869-1883.
24. Martin LP, Hamilton TC, Schilder RJ,. (2008) Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14: 1291-1295.
25. Pilgrim CH, Brettingham-Moore K, Pham A, Murray W, Link E, Smith M, et al. (2011) mRNA gene expression correlates with histologically diagnosed chemotherapy-induced hepatic injury. HPB 13: 811-816.
26. Lutsenko S, Barnes NL, Bartee MY, Dmitriev OY,. (2007) Function and regulation of human copper-transporting ATPases. Physiol Rev 87: 1011-1046.
27. Huster D,. (2010) Wilson disease. Best Pract Res Clin Gastroenterol 24: 531-539.
28. Fukushima-Uesaka H, Saito Y, Maekawa K, Kurose K, Sugiyama E, Katori N, et al. (2009) Genetic polymorphisms of copper and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients. Drug Metab Pharmacokinet 24: 565-574.
29. Nakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu MP, Dufour P, et al. (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247: 118-124.
30. Kweekel D, Guchelaar HJ, Gelderblom H,. (2008) Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev 34: 656-669.
31. Marsh S, Hoskins JM,. (2010) Irinotecan pharmacogenomics. Pharmacogenomics 11: 1003-1010.